

# Special Issue

## Tumour Angiogenesis

### Message from the Guest Editor

Tumor angiogenesis is critical for both tumor progression and metastasis. Hence targeting tumor angiogenesis as a therapeutic anticancer approach has been actively pursued for many years. Despite the initial success in animal tumor models and some degree of effectiveness in prolonging the survival of human cancer patients, limitations of efficacy plus inherent as well as acquired resistance in human cancers still plague this therapeutic approach. Hence, further understanding of the molecular and cellular mechanisms of tumor angiogenesis are essential for the advancement of effective antiangiogenic therapy. This special issue will focus on new advancement in the biology and drug targeting of tumor angiogenesis. We are looking forward to your contributions.

---

### Guest Editor

Dr. Ruowen Ge

Department of Biological Sciences, National University of Singapore,  
Singapore 117558, Singapore

---

### Deadline for manuscript submissions

closed (30 April 2013)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/1668](http://mdpi.com/si/1668)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](http://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)